UK patent office issued the Microscaffold patent (GB2544748A)

Link to Full Article On 23 June 2020, the UK patent office issued the Microscaffold patent (GB2544748A). Our custom Microscaffolds can be made from a large variety of materials and sizes, tailored towards their desired application. Their open, porous, three-dimensional structure allows for facile cell attachment and integration over a large range of cell types. These scaffolds […]

Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections

Link to Full Article Non-dilutive funding to be used to advance the company’s second phage-based therapeutic candidate in a Phase 1b/2 clinical study MARINA DEL REY, Calif., June 17, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today […]

ARECOR PRESENTS POSITIVE RESULTS FOR THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA-RAPID ACTING INSULIN

Link to Full Article AT247 delivers significantly accelerated absorption of insulin compared to best in class treatments NovoRapid® and Fiasp®   Cambridge, UK., 15 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, presented positive results for the Phase I clinical trial of its ultra-rapid acting […]

ARECOR ANNOUNCES ORAL PRESENTATION OF THE FIRST PHASE I CLINICAL TRIAL OF AT247, A NOVEL ULTRA RAPID ACTING INSULIN, AT THE AMERICAN DIABETES ASSOCIATION 80TH SCIENTIFIC SESSIONS

Cambridge, UK., 10 June 2020: Arecor Limited (“Arecor” or “the Company”), the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its abstract titled ‘Phase I Study Investigating the PD, PK and Safety of AT247 in comparison with NovoRapid® and Fiasp®’, has been selected for oral presentation at the upcoming American Diabetes […]

Saluda Medical Appoints Jim Schuermann as President and Robert Gaffney as Chief Operating Officer

Link to Full Article Strengthens corporate leadership as company moves toward global commercialization Artarmon, Australia – June 9, 2020 – Saluda Medical Pty Limited (“Saluda Medical”), a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with debilitating neurological disorders, today announced the key leadership appointments of Jim Schuermann as President and Robert Gaffney as Chief Operating […]

CALCIMEDICA APPOINTS ROBERT N. WILSON, FORMER J&J VICE CHAIRMAN AS CO-CHAIRMAN OF THE BOARD OF DIRECTORS AND ERIC W. ROBERTS AS VICE CHAIRMAN

Former Johnson & Johnson Vice Chairman, Robert N. Wilson, joins CalciMedica as Co-Chairman  Board Member, Eric W. Roberts, named Vice Chairman and Chairman of the Strategic Transactions and Finance Committee of the Board LA JOLLA, Calif., June 2, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels […]

CALCIMEDICA RAISES $15 MILLION IN SERIES C FINANCING ROUND LED BY VALENCE LIFE SCIENCES

Link to Full Article Funds to support ongoing clinical trials in patients with COVID-19 pneumonia and commercial manufacturing of Auxora™  LA JOLLA, Calif., May 22, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced it has […]

CALCIMEDICA ANNOUNCES THAT FDA HAS STRONGLY RECOMMENDED MOVING TO A BLINDED PLACEBO-CONTROLLED TRIAL WITH AUXORA™ IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA

LA JOLLA, Calif., May 21, 2020 – CalciMedica Inc. (“CalciMedica” or the “Company), a clinical-stage biotechnology company targeting calcium release-activated calcium (CRAC) channels for the treatment of acute and severe inflammatory diseases, today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) regarding the Company’s ongoing study of Auxora™ (formerly called […]

Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update

Link to Full Article MARINA DEL REY, Calif., May 14, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the first quarter of 2020 and provided a corporate and clinical update. Key First Quarter 2020 and Subsequent […]

12 May 2020 – Posting of Annual Report and Notice of AGM

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Posting of Annual Report and Accounts, and Notice of AGM Brighton, United Kingdom – 12 May 2020 – Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces that […]